Stay updated on Pembrolizumab Post-TACE in Liver Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange Detected- Added a government operating status notice and a version bump to v3.2.0. - Removed the old version tag v3.1.0.SummaryDifference4%
- Check17 days agoChange DetectedAdded new oncology-related terms and upgraded revision to v3.1.0; removed the Liver Cancer topic and old v3.0.2 revision.SummaryDifference1%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedUpdated to Revision: v3.0.2. Removed the Back to Top element.SummaryDifference0.2%
- Check38 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check46 days agoChange DetectedThe web page has added significant information regarding a facility name, location, and relevant publications related to liver cancer and pembrolizumab, while removing various location terms and resources previously listed.SummaryDifference8%
- Check60 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab Post-TACE in Liver Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.